Global pharmaceutical company AstraZeneca is preparing to begin selling the Chinese-developed lung cancer drug sunvozertinib in the United States, moving to close an access gap that prompted dozens of American patients to fly to Shanghai to buy the medication themselves. Marketed in the U.S. under the brand name Zegfrovy and developed by Shanghai-based Dizal Pharmaceutical, the targeted treatment received accelerated approval from the U.S. Food and Drug Administration on July 2, 2025. Despite that regulatory clearance, the medication remained unavailable in American pharmacies for over a year while commercial distribution arrangements were finalized.

The prolonged delay between federal approval and pharmacy availability forced patients with a rare, aggressive form of lung cancer to look overseas. According to the South China Morning Post, AstraZeneca confirmed on October 22, 2026, that it would bring the medication to the U.S. market following public criticism over the slow rollout. While KFF Health News reports that AstraZeneca is targeting U.S. availability by the start of 2027 after signing a worldwide development and distribution agreement with Dizal on September 1, 2026, a separate report from Medical Daily indicates the launch could happen by the end of 2026.

Why American Patients Traveled to China for Treatment

For Americans diagnosed with advanced lung cancer, the wait for domestic commercial distribution proved untenable. Sunvozertinib had already been approved and stocked in Chinese pharmacies since 2023, creating an unusual dynamic where a cutting-edge therapy was accessible in Asia long before patients could obtain it through U.S. health systems.

The plight of Debbie Doppelt, a 60-year-old Manhattan jeweler diagnosed in 2023 with an unusual form of lung cancer that primarily affects nonsmokers, highlights the consequences of the distribution lag. By January 2025, after Doppelt underwent surgery and chemotherapy, the cancer had spread to her brain, according to KFF Health News. Because the FDA had not yet approved sunvozertinib at that time and Doppelt did not qualify for relevant U.S. clinical trials, New York City hospitals had few effective options left to offer her.

When a physician remarked to her son, Max Doppelt, that his mother could simply buy the drug at a pharmacy if she were in China, the family took action. Through personal contacts in China, they initially secured a small supply, and Max Doppelt subsequently flew to Shanghai to obtain a refill. According to Medical Daily, he brought back 26 boxes of the medication at a reported cost of about $10,000.

Max Doppelt, who serves as chief executive of the clinical trial consultancy Patient Data Vault, told the South China Morning Post that he was deeply grateful for the development work done by companies in China, crediting the drug with saving his mother's life. While no formal medical organization or physician network has guided patients abroad, word spread informally among patient advocacy networks. Max Doppelt estimated that he knows of at least 30 Americans who traveled to China to purchase sunvozertinib while it remained absent from the U.S. market through mid-October 2026.

How Sunvozertinib Targets Specific Lung Tumors

Sunvozertinib is not a broad-spectrum chemotherapy, but rather a targeted therapy engineered for a specific genetic profile of lung cancer. The FDA granted accelerated approval for the medication to treat adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors carry epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

Under the FDA guidelines, the drug is indicated for patients whose disease has progressed during or after standard platinum-based chemotherapy. EGFR exon 20 insertion mutations represent a distinct subset of lung cancer that frequently affects people who have never smoked. Historically, tumors driven by these specific genetic insertions have been difficult to treat, as they often do not respond well to earlier generations of targeted EGFR inhibitors or conventional immunotherapy.

By targeting the exact protein mutation driving tumor growth, sunvozertinib offers a tailored oral option for patients whose cancer has resisted initial rounds of systemic therapy. Because the July 2025 clearance was granted under the FDA's accelerated approval pathway—a program designed to speed up access to medications for serious conditions that fill an unmet medical need—continued approval generally requires follow-up confirmatory data to verify long-term clinical benefit.

A Shifting Global Biotech Landscape

The cross-Pacific trips made by American patients reflect a broader structural shift in global pharmaceutical development. For decades, American medical centers and pharmaceutical firms dominated the development of novel oncology therapies, contributing to a reduction of roughly one-third in the U.S. cancer death rate since 1990. China, by contrast, was primarily viewed as a supplier of generic medications and raw chemical precursors.

Following challenges in vaccine and drug development during the COVID-19 pandemic, China overhauled its domestic biotechnology sector. By 2025, China accounted for as much as 46% of new drugs tested worldwide, according to KFF Health News. In addition to targeted oral drugs like sunvozertinib, Americans and Europeans have increasingly traveled to China to enroll in clinical trials for CAR-T cell therapies, an area of oncology where Chinese researchers have established a strong global presence.

Sam Rasty, chief executive of the biotech firm FynderBio, noted in the KFF Health News report that venture capital now flows heavily toward early-stage clinical research in China and Australia, where regulatory frameworks allow initial human studies to launch much faster than in the United States. Major U.S. and European pharmaceutical companies have responded by signing multibillion-dollar licensing agreements with Chinese biotech developers, such as AstraZeneca's September 2026 global pact with Dizal Pharmaceutical. At the same time, the rapid shift has raised concerns among U.S. lawmakers regarding domestic pharmaceutical dependency, prompting the Trump administration in June 2026 to initiate Operation TrialBlazer, a federal effort aimed at streamlining certain FDA regulatory processes to keep clinical trials in the United States.

What This Means for Patients and Families

For American patients living with EGFR exon 20-mutated non-small cell lung cancer, AstraZeneca's move to commercialize Zegfrovy domestically removes the immense financial and logistical hurdle of traveling to Asia for care. Purchasing medications overseas requires patients to pay thousands of dollars out of pocket without U.S. health insurance coverage, navigate international customs with prescription drugs, and manage complex cancer treatment across disconnected healthcare systems.

When will Zegfrovy be available in U.S. pharmacies, and how much will it cost?

AstraZeneca has indicated that U.S. commercial availability is targeted by the start of 2027, though some reporting suggests sales could begin by late 2026. The company has not yet publicly disclosed the official U.S. list price or specific insurance coverage tiers. While one patient's family reported paying roughly $10,000 for 26 boxes in Shanghai, domestic U.S. pricing and out-of-pocket costs will depend on individual health insurance formularies and patient assistance programs once the drug launches.

Who qualifies for the medication in the United States?

Patients must have confirmed locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations, as detected by an FDA-approved diagnostic test, and their cancer must have progressed on or after platinum-based chemotherapy. Patients and caregivers should consult their oncologist to review biomarker testing results and discuss whether Zegfrovy is appropriate for their treatment plan.

Sources